DE EN

Press Releases 2019

Zürich Switzerland 17th of April 2019 – HypoPet AG today announced the publication of important preclinical data for their cat allergy vaccine, HypoCatTM.

The data were published online 17th of April 2019 in an article entitled “Immunization of cats to induce neutralizing antibodies against Fel d 1, the major feline allergen in human subjects. “in the Journal of Allergy and Clinical Immunology.

Go to article
Download media release here

Zürich Switzerland 19th of March 2019 – HypoPet AG today announced the publication of proof of principle data for a vaccine with the potential to translate into a novel therapy for osteoarthritic pain in companion animals. The data were published online 12th of March 2019 in an article entitled “Active immunisation targeting nerve growth factor attenuates chronic pain behaviour in murine osteoarthritis” in the Annals of the Rheumatic Diseases.

Go to the article
Download media release here

9th January 2019 - HypoPet to present at Animal Health Investment Forum London
HypoPet AG today announced that it has been selected as a finalist to present at the prestigious Animal Health Investment Europe Forum in February 2019. The Animal Health Innovation showcase provides an opportunity for the most exciting and innovative emerging animal health companies, selected by committee, to present their breakthrough innovations and business to investors and industry professionals.

Company founder and CSO Martin Bachmann will give HypoPet’s 10 min presentation in London, Aldersgate on the 26th of February.

Press Releases 2018

Proof of concept data for HypoPet’s virus-like particle vaccine for treating canine atopic dermatitis published in leading allergy journal

Zürich Switzerland 11th of April 2018 – HypoPet AG today announced the publication of Proof of Concept data for a vaccine for treating canine atopic dermatitis (CAD) in the renowned Journal of Allergy and Clinical Immunology. The data were published online 4th of April 2018 in an article entitled “Vaccination against IL-31 for the treatment of atopic dermatitis in dogs”.

Download media release here

Press releases 2017

HypoPet AG merges with Saiba Animal Health GmbH

In May 2017 HypoPet AG announced a merger with Saiba Animal Health GmbH. Saiba Animal Health's CAD vaccine (partnered with Benchmark Holdings PLC) and product pipeline of novel vaccine candidates subsequently became part of HyopPet's product candidate pipeline .

Fusion of Saiba Animal Health and HypoPet AG

Press release 2015

Licensing Deal for Canine Atopic Disease vaccine

Benchmark secures licensing deal for Canine Atopic Diseases vaccine.

Link to the announcement

Press Releases 2014

Agreement for HypoCat

Benchmark Holdings PLC announces an agreement with HypoPet AG for HypoCat

Link to the agreement

2013 Press Releases

Article of the newspaper Neue Luzerner Zeitung

Download article of Neue Luzerner Zeitung

Press release of the University of Zürich

Download the University Hospital of Zürich release

Hypopet release of winning Swiss Technology Award

Download Hypopet release of winning Swiss Technology Award

Article of the newspaper Thurgauer Zeitung / St. Galler Tagblatt

Download article of Thurgauer Zeitung / St. Galler Tagblatt

Article of the newspaper Neue Zürcher Zeitung

Download article of Neue Zürcher Zeitung